<DOC>
	<DOC>NCT02683928</DOC>
	<brief_summary>The purpose of this study is to determine the effect of GBR 830 on biomarkers in AD/ eczema to enable further studies in this indication.</brief_summary>
	<brief_title>To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)</brief_title>
	<detailed_description>Approximately 40 patients who meet eligibility criteria will undergo baseline assessments and randomize to receive GBR 830 or placebo. Safety and tolerability of GBR 830 will be evaluated in patients with AD/eczema.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male or female, 18 years or older Moderate to severe atopic dermatitis that has been present for greater than 1 year from screening with BSA â‰¥10%. Treatment with systemic corticosteroids within 4 weeks before randomization, and topical steroids/tacrolimus and or/pimecrolimus within 1 week before the randomization (except emollients, and mild steroids (class 6 or 7) Any celldepleting agents including but not limited to rituximab: within 6 months prior to the baseline visit or until lymphocyte and CD 19+ lymphocyte counts return to normal, whichever is longer. Other biologics: within 5 halflives or 8 weeks prior to the baseline visit, whichever is longer. Allergen immunotherapy within 6 months before the baseline visit. Patient with history of serious local infection and systemic infection Patient with history or current evidence of diseases such as tuberculosis, malignant disease, other inflammatory or autoimmune disease or HIV or Hepatitis B or C positive. Pregnant or breastfeeding women or women planning to become pregnant or breastfeed during the study or unwilling to use adequate birth control, if of reproductive potential and sexually active</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>